It is known that MET confers resistance to targeted agents including BRAF inhibitors in malignant melanoma and the EGFR inhibitor gefitinib in NSCLC, through activating oncogenic signalling pathways such as PI3K/AKT [25–27]. The gene discussed is MET; the disease is non-small cell lung carcinoma.